BARCELONA, Spain, April 19,
2024 /PRNewswire/ -- Grifols, S.A. ("Grifols")
(MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company
and leading manufacturer of plasma-derived medicines, today
announces the filing of its Annual Report on Form 20-F for the
fiscal year ended December 31, 2023,
with the United States Securities and Exchange Commission
("SEC").
Grifols' annual report on Form 20-F provides investors with an
overview of the company's governance practices, including
information about the Board of Directors and its committees,
executive compensation, and risk management. This information is
critical for stakeholders to make informed decisions about
investing in the company, engaging with the company on
sustainability and governance issues, and assessing the company's
long-term value creation potential.
Grifols' Annual Report on Form 20-F includes, among other
disclosures, the financial statements of Grifols for its fiscal
year ended December 31, 2023 in
accordance with International Financial Reporting Standards (IFRS)
as adopted by the International Accounting Standards Board that
were audited and certified in compliance with internal control over
financial reporting by the auditing firm KPMG Auditores, S.L. for
the years 2021, 2022 and 2023.
In addition to the financial statements, the annual report
includes management's discussion and analysis (MD&A) of the
financial condition and results of operations, as well as
information about the company's key performance indicators and
sustainability initiatives. The MD&A provides insights into the
company's performance over the past year, highlighting key drivers
of growth and areas of concern.
Grifols' share capital is represented by 426,129,798 ordinary
shares (Class A), with a nominal value of EUR 0.25 per share, and 261,425,110 non-voting
shares (Class B), with a nominal value of EUR 0.05 per share. Grifols' ordinary shares
(Class A) are listed on the Spanish stock market and form part of
the IBEX-35 (GRF). Non-voting shares (Class B) are also listed on
the Spanish stock market (GRF.P) and on NASDAQ (GRFS) through ADRs
(American Depositary Receipts).
The annual report on Form 20-F can be accessed electronically
through Grifols' website at http://www.grifols.com/en/investors and
the SEC's website at http://www.sec.gov.
Grifols will deliver, within a reasonable time after request, a
hard copy of the annual report on Form 20-F, including its complete
audited financial statements, free of charge, to any shareholder
upon request. To request a hard copy, shareholders may contact
Grifols by email at investors@grifols.com to the attention of
Grifols' Investor Relations & Sustainability, Re: 2023 Annual
Report on Form 20-F.
About Grifols
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the
health and well-being of people around the world. A leader in
essential plasma-derived medicines and transfusion medicine, the
company develops, produces, and provides innovative healthcare
services and solutions in more than 110 countries.
Patient needs and Grifols' ever-growing knowledge of many
chronic, rare and prevalent conditions, at times life-threatening,
drive the company's innovation in both plasma and other
biopharmaceuticals to enhance quality of life. Grifols is focused
on treating conditions across a broad range of therapeutic areas:
immunology, hepatology and intensive care, pulmonology, hematology,
neurology, and infectious diseases.
A pioneer in the plasma industry, Grifols continues to grow its
network of donation centers, the world's largest with over 390
across North America, Europe, Africa and the Middle East, and China.
As a recognized leader in transfusion medicine, Grifols offers a
comprehensive portfolio of solutions designed to enhance safety
from donation to transfusion, in addition to clinical diagnostic
technologies. It provides high-quality biological supplies for
life-science research, clinical trials, and for manufacturing
pharmaceutical and diagnostic products. The company also supplies
tools, information and services that enable hospitals, pharmacies
and healthcare professionals to efficiently deliver expert medical
care.
Grifols, with more than 23,000 employees in more than 30
countries and regions, is committed to a sustainable business model
that sets the standard for continuous innovation, quality, safety,
and ethical leadership.
In 2023, Grifols' economic impact in its core countries of
operation was EUR 9.6 billion. The
company also generated 193,000 jobs, including indirect and
induced.
The company's class A shares are listed on the Spanish Stock
Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols
non-voting class B shares are listed on the Mercado Continuo
(MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For
more information about Grifols, please visit www.grifols.com.
For more information, please visit www.grifols.com
View original
content:https://www.prnewswire.com/news-releases/grifols-2023-annual-report-on-form-20-f-filed-with-the-sec-302122482.html
SOURCE Grifols